The National Medical Products Administration recently approved Seloxavir Marboxil tablets for the market, with Jumpcan Pharmaceutical Group in Taixing city, Jiangsu province, being its exclusive promoter and distributor in the Chinese market.
As a new anti influenza drug with global independent intellectual property rights, this product is suitable for the treatment of patients with influenza A and B, and patients only require one dose of medication for the entire course of treatment.
A bird's eye view of Jumpcan Pharmaceutical Group. [Photo/WeChat account: txfabu]
The medicine was independently developed by Nanjing Zenshine Pharmaceutical, a clinical stage biopharmaceutical company focusing on small molecule therapeutics in cancer, viral infection and inflammation.
Jumpcan and Zenshine partnered in 2023, relying on the former's advantageous resources and drug quality reputation in the respiratory and pediatric fields.